Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
about
Oncolytic viruses as immunotherapy: progress and remaining challengesTrial Watch:: Oncolytic viruses for cancer therapyOncolytic viruses as anticancer vaccinesOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesPermissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityHandling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.Designing Herpes Viruses as Oncolytics.Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategiesImmunotherapeutic potential of oncolytic vaccinia virus.Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells.STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes VirusesEnhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma.Oncolytic Immunotherapy for Treatment of Cancer.Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo.Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer CellsReovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.Proteomic Analysis of Secretomes of Oncolytic Herpes Simplex Virus-Infected Squamous Cell Carcinoma Cells.Oncolytic Virotherapy and the Tumor Microenvironment.High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axisOncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cellsSafety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
P2860
Q26745942-78E11AC1-07F7-4B16-A257-AC9456A15428Q27021951-EC42D782-375E-444F-846C-4D25468782AFQ27025600-0D348C33-F802-4140-B945-4CB9B7D0ACC2Q33679505-85011007-C228-4910-AEBB-FB170CC94441Q33743847-FEC06C31-670C-41DB-9EDB-18A8385BE01BQ35161325-0CE9C6DE-A997-4161-A862-60A7698172DEQ35224606-C5791995-6463-4C2F-97FF-31F660926A5AQ35740932-1F2486E5-9453-4F3D-8E0C-E3D4C5867021Q36142487-DCEFEFE9-B6C8-4017-A444-DFCB0C30FBB3Q36380295-DA21CB09-313D-4259-8749-B0F9AFD329AFQ36547314-68D88A15-E9F2-4554-B52B-DC52AB4570EEQ36700481-45F9C5F6-E7F4-473C-8824-DDF77047B8E9Q37502464-B01861AA-FD26-4C66-91F2-1264F8C8CB88Q37707676-0FBA7BF9-C79C-4F84-921C-A305541C87DFQ38139255-0F18F30A-C5B7-475D-9BBB-B84868FC4FA4Q38225561-C052C5FD-1ED1-41A9-9522-0CE95E913724Q38348844-977C8535-B139-4770-9DDE-FF3650A06C16Q38357137-709096C5-8CA9-4D1A-BD8C-DFD745FF60F8Q38785456-AEC21252-2480-4BF8-945A-DE978BCC3740Q38793802-BFD1E1C7-7899-4CF3-AFCB-97DDC73F3575Q38795324-0489E52C-F6C0-40CE-B1B2-12A19B123187Q38845195-B43D33D2-C88F-4D71-A7ED-3DDFB0CA4186Q38848223-A665B2EE-7084-48AD-8041-47DC45727508Q38857183-383CE503-D578-4421-B425-9C5E5836B744Q39339386-47CC4221-2575-47AE-B5A4-0AD01A8E1E1DQ40064004-7A46ADCC-C50B-4CA7-AF22-6F06BCFE10A1Q41688010-522C1DB6-6AD6-4A71-AAC7-011A604A515AQ41919532-48942F91-EF35-4EF3-8CE2-555C5EF3A761Q47549912-7A427F2F-5A51-4BE0-BCFE-376A33CC7551Q47560690-A6937ADD-084E-44BF-B155-9BFB5FED8522Q52726371-5B96AB96-0FC4-4682-B501-B1EF10636D45Q55085319-8C4EE315-364A-414B-9284-865188779E9EQ55510540-70015E59-6400-4CCE-ABC3-EB4D3C00AB75Q58711851-E1612159-90ED-4138-B73F-5CAA23238F4DQ58804576-F33B832A-BEC6-48F3-B04E-F12C38925D19Q59117175-F467DF2D-50AF-447F-9323-C4F04C7C579F
P2860
Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Immunogenic HSV-mediated oncol ...... butes to therapeutic efficacy.
@en
type
label
Immunogenic HSV-mediated oncol ...... butes to therapeutic efficacy.
@en
prefLabel
Immunogenic HSV-mediated oncol ...... butes to therapeutic efficacy.
@en
P2093
P2860
P356
P1433
P1476
Immunogenic HSV-mediated oncol ...... butes to therapeutic efficacy.
@en
P2093
Brian D Lichty
Graydon Simmons
Samuel T Workenhe
William P Halford
P2860
P304
P356
10.1038/MT.2013.238
P577
2013-10-09T00:00:00Z